Headlines about Horizon Therapeutics (NASDAQ:HPTX) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Horizon Therapeutics earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.3476201235033 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
NASDAQ:HPTX remained flat at $$45.99 on Monday. Horizon Therapeutics has a 52-week low of $20.23 and a 52-week high of $46.96.
TRADEMARK VIOLATION WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/16/horizon-therapeutics-hptx-earns-media-impact-score-of-0-25.html.
Horizon Therapeutics Company Profile
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.